X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
All 20 subjects received the first dose of V-306 or placebo, as planned and early clinical experience is encouraging with no adverse events reported to date.
Lead Product(s): V-306
Therapeutic Area: Infections and Infectious Diseases Product Name: V-306
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
The financing will ensure the company can complete the phase 1 clinical trial of its lead asset V-306 in RSV, advance pre-clinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.
Lead Product(s): V-306
Therapeutic Area: Infections and Infectious Diseases Product Name: V-306
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
